Similar efficacy for phase i trials in comparison with DTIC for advanced malignant melanoma: An analysis of melanoma outcomes in CTEP-sponsored phase i trials 1995-2011

Melanoma Research

Volumn 23, Issue 2, 2013, Pages 152-158

  Luke, Jason J ^a   Rubinstein, Lawrence V ^b   Smith, Gary L ^b   Ivy, S Percy ^b   Harris, Pamela J ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

chemotherapy; CTEP; dacarbazine; melanoma; phase I

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; IMMUNOLOGIC AGENT; TEMOZOLOMIDE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84874950725     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32835f73b2     Document Type: Article

References (29)

1. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
4. Sondak VK, Flaherty LE. Targeted therapies: Improved outcomes for patients with metastatic melanoma. Nat Rev Clin Oncol 2011; 8:513-515.
5. Lipsett MB. On the nature and ethics of phase I clinical trials of cancer chemotherapies. JAMA 1982; 248:941-942.
6. Joffe S, Miller FG. Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol 2006; 24:2987-2990.
7. Emanuel EJ. A phase I trial on the ethics of phase I trials. J Clin Oncol 1995; 13:1049-1051.
8. Agrawal M, Emanuel EJ. Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA 2003; 290:1075-1082.
9. Roberts TG Jr, Goulart BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004; 292:2130-2140.
10. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005; 352:895-904.
11. Annas GJ. The changing landscape of human experimentation: Nuremberg, Helsinki, and beyond. Health Matrix Clevel 1992; 2:119-140.
12. Olmos D, A'Hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, et al. Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol 2012; 30:996-1004.
13. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 2009; 27:2692-2696.
14. Fu S, Hong DS, Naing A, Wheler J, Falchook G, Wen S, et al. Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program. J Clin Oncol 2011; 29:3547-3552.
15. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 2010; 16:1289-1297.
16. Italiano A, Massard C, Bahleda R, Vataire AL, Deutsch E, Magne N, et al. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 2008; 19:787-792.
17. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, et al. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for Targeted Therapy Experience. Clin Cancer Res 2012; 18: 2922-2929.
18. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, et al. Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer 2009; 115:1091-1099.
19. Miller AB, Hoogstraten B, Staquet M,Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
21. Cancer Therapy Evaluation Program. 2012Common Toxicity Criteria for Adverse Events (CTCAE). Bethesda, MD. Available at: http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm [Accessed 17 April 2012].
22. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745-2751.
23. Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011; 47:1476-1483.
24. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22:1118-1125.
25. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.
26. Hoekstra R, Verweij J, Eskens FA. Clinical trial design for target specific anticancer agents. Invest New Drugs 2003; 21:243-250.
27. Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist 2002; 7:401-409.
28. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420.
29. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-2454.